.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD07_Tolterodine.Tolterodine .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD07_Tolterodine.Tolterodine| name: | Tolterodine |
| ATC code: | G04BD07 | route: | oral |
| n-compartments | 2 |
Tolterodine is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is approved and widely used today as a symptomatic treatment for overactive bladder.
Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration of tolterodine immediate release formulation.
Olsson, B, & Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clinical therapeutics 23(11) 1876–1888. DOI:10.1016/s0149-2918(00)89083-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11768839
Oishi, M, et al., & Malhotra, B (2014). Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. Journal of clinical pharmacology 54(8) 928–936. DOI:10.1002/jcph.274 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24619889
Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. Clinical pharmacokinetics 42(14) 1243–1285. DOI:10.2165/00003088-200342140-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14606931